Last reviewed · How we verify
V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
The study evaluates the immunogenicity, safety and tolerability of V501 in preadolescent females
Details
| Lead sponsor | Merck Sharp & Dohme LLC |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 107 |
| Start date | Mon Dec 11 2006 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Sep 18 2009 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- HPV Infections
Interventions
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)
- Comparator: Placebo (unspecified)